CRL
TentativeAI MemoPost-earnings T+3Charles River Laboratories International
As of 2026-08-08/Post-earnings T+3/Confidence high
Data freshness
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Report quality notice
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Action
—
Confidence
high
Horizon
—
Key catalyst
Q2 results and FY2026 guidance raise • 2026-08-05
Base target: $282 / p=55% prob
Biggest risk
RMS remains weak, DSA costs compressed non-GAAP margins, and the GAAP result included a $63.7 million divestiture-related loss. The key risk is that the guidance raise reflects normalization already expected by investors rather than durable acceleration.
Invalidation
Break below $220 or thesis failure.
What would change my mind?
The Q2 print appears better than the packet’s pre-release Zacks estimates of $970.8 million revenue and $2.72 non-GAAP EPS, while the company raised full-year guidance and reported improving DSA demand and a multiyear-high book-to-bill [#PR-EARNINGS-2026-07-30] [#SEC-8K-2026-08-05].
Research note
Recommendation
—
Confidence
high
As of
2026-08-08
Base target
$282
p=55%
Bull target
$315
p=25%
Bear target
$220
p=20%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- DSA booking and margin follow-through
- RMS weakness and cost execution risk
- Portfolio refocus and modernization
BearKey bullets
- Divestiture-related losses and portfolio restructuring may continue to distort GAAP earnings and execution.
- Higher DSA study-related direct costs and corporate expenses could delay margin recovery.
- Post-print analyst coverage remains thin: the available Mizuho target increase retained a Neutral rating, while broader estimate-revision data are unavailable.
WatchKey bullets
- Q2 results and FY2026 guidance raise
Summary
High-level snapshot
Recommendation
-
Model confidence
high
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+3
Base case: $282 (p=55%)
Target spread vs base: +12% / -22%
Scenario probabilities
Bull Target: $315 (p=25%)Base Target: $282 (p=55%)Bear Target: $220 (p=20%)
Commentary
The post-earnings tone is positive because Q2 results exceeded the packet’s pre-release framing, guidance increased, and DSA bookings improved. CRL closed at the RankAlpha anchor of $265.51 on August 6 and was quoted at $267.49 on August 7, a modest approximately 0.7% follow-through rather than an outsized repricing. Market reaction was therefore constructive but restrained, while the available analyst revision signal remained mixed. Social sentiment, options skew, short interest, and Glassdoor data are unavailable; this supports cautious monitoring rather than a high-conviction rerating call.
As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
The Q2 print appears better than the packet’s pre-release Zacks estimates of $970.8 million revenue and $2.72 non-GAAP EPS, while the company raised full-year guidance and reported improving DSA demand and a multiyear-high book-to-bill [#PR-EARNINGS-2026-07-30] [#SEC-8K-2026-08-05].
Bear Case
RMS remains weak, DSA costs compressed non-GAAP margins, and the GAAP result included a $63.7 million divestiture-related loss. The key risk is that the guidance raise reflects normalization already expected by investors rather than durable acceleration.
Drivers
Scannable catalysts and supporting factors
- DSA booking and margin follow-through
- RMS weakness and cost execution risk
- Portfolio refocus and modernization
Scenarios
Bull Target (Scenario probability)
$315 / p=25% prob
Base Target (Scenario probability)
$282 / p=55% prob
Bear Target (Scenario probability)
$220 / p=20% prob
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.72
Social Sentiment (7d)
-
Events
Other notable items detected
- EVENT2026-08-05Q2 results and FY2026 guidance raiseQ2 revenue was $1.00 billion, non-GAAP EPS was $3.02, organic revenue growth reached 0.1%, and management raised organic revenue guidance by 150 basis points and non-GAAP EPS guidance by $0.25 at the midpoint, citing improving DSA demand and better Manufacturing performance [#SEC-8K-2026-08-05].Prob 100.00% • Move 4.00% • Priced-in 75.00%
Short-term Catalysts
Next few weeks
- DSA booking and margin follow-through2026-09-30The highest DSA net book-to-bill in nearly four years and broad-based demand improvement provide near-term support, but investors need evidence that bookings convert into revenue and margins after the guidance raise [#SEC-8K-2026-08-05].Prob 60% • Move 3% • Priced-in 65%
- RMS weakness and cost execution risk2026-09-30RMS organic revenue declined 1.4% in Q2, while non-GAAP operating margin fell year over year because of higher DSA study-related direct costs and corporate costs. A renewed demand or margin setback could pressure the raised outlook [#SEC-8K-2026-08-05].Prob 40% • Move -5% • Priced-in 35%
Long-term Catalysts
Months to a year
- Portfolio refocus and modernization2026-12-31Completed divestitures, the Lilly TuneLab collaboration, and an AI-enabled digital pathology solution support a more focused regulated-testing portfolio and potential efficiency gains, but financial contribution remains unproven [#SEC-8K-2026-08-05].Prob 50% • Move 8% • Priced-in 35%
Risks
- Divestiture-related losses and portfolio restructuring may continue to distort GAAP earnings and execution.
- Higher DSA study-related direct costs and corporate expenses could delay margin recovery.
- Post-print analyst coverage remains thin: the available Mizuho target increase retained a Neutral rating, while broader estimate-revision data are unavailable.
- RMS demand weakness, especially in North America and research model services.
- Recent insider open-market sales are a secondary caution signal, not evidence of operating deterioration [#SEC-FORM4-2026-08-06].
- The guidance raise and DSA recovery narrative may already be substantially reflected in the share price.
Peers
| Symbol | Summary |
|---|---|
| IQV | Useful strategic and transaction read-through for discovery services and data capabilities, but its larger clinical and technology mix limits valuation comparability. |
| ICLR | Direct CRO comparator, though ICON has greater clinical-research exposure and is not a clean match for Charles River’s preclinical and safety-assessment mix. |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-08-08